DOCS DOCS
Company Profile ↓Company Overview
DOCS (DOCS) is a publicly traded company listed on . The valuation, growth and price-trend signals below summarize what matters most to investors and traders evaluating the stock.
Why Investors Should Care
Generates a return on equity of 20.6%, reflecting efficient use of shareholder capital.
Return on capital employed stands at 22.2%.
Net profit has compounded at 36.9% per year over the last five years.
Revenue has grown at a 33.0% CAGR over the past five years.
Maintains a net profit margin of 30.4%.
Generates positive free cash flow, funding growth and shareholder returns internally.
Recent Developments
- Mar 2026 Revenue of $644.86M (+13.1% YoY); net profit $196.05M.
- Trailing 12 Months Year-on-year growth — revenue +13.1%, earnings -12.2%.
- 5-Year Trend Long-term compounding — revenue CAGR 33.0%, profit CAGR 36.9%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | 33.02% |
| 1 Year: | 13.05% |
Compounded Profit Growth
| 5 Years: | 36.93% |
| 1 Year: | -12.16% |
Stock Price Performance
| 1 Year: | -62.90% |
| 6 Months: | -37.93% |
| 3 Months: | -16.07% |
| 1 Month: | -4.88% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMAAbove
- Price vs 200-DMABelow
- RSI (14)52.34 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- Strong return on equity of 20.6%.
- Healthy ROCE of 22.2%.
- Excellent profit margin of 30.4%.
- Compounding revenue at 33.0% over 5 years.
- Profit CAGR of 36.9% over 5 years.
- Generates positive free cash flow.
CONS
- Trading 71.2% below its 52-week high.
- In a downtrend (50-DMA below 200-DMA).
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Jun 2020 | Sep 2020 | Dec 2020 | Jun 2021 | Sep 2021 | Dec 2021 | Jun 2022 | Sep 2022 | Dec 2022 | Jun 2023 | Sep 2023 | Dec 2023 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 36.39M | 45.11M | 58.71M | 72.67M | 79.35M | 97.88M | 90.64M | 102.19M | 115.26M | 108.47M | 113.61M | 135.28M | 126.68M | 136.83M | - | 138.29M | 145.91M | 168.53M | 185.05M | 145.37M |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 14.47M | 15.79M | 16.43M | 18.70M | 19.41M |
| Gross Profit | 28.51M | 37.66M | 50.84M | 64.68M | 70.40M | 86.79M | 77.56M | 88.97M | 101.74M | 95.32M | 100.85M | 123.09M | 113.13M | 123.16M | - | 123.82M | 130.12M | 152.10M | 166.35M | 125.97M |
| Operating Expenses | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 75.14M | 75.60M | 88.42M | 94.46M | 101.14M |
| Operating Income | 2.08M | 10.44M | 17.94M | 24.88M | 24.95M | 35.79M | 21.68M | 32.10M | 38.48M | 29.68M | 33.79M | 58.55M | 46.05M | 53.14M | - | 48.68M | 54.52M | 63.68M | 71.90M | 24.83M |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 51.51M | 57.31M | 67.15M | 75.89M | 28.96M |
| Interest Expense | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Pretax Income | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 58.39M | 64.15M | 72.94M | 80.80M | 32.12M |
| Tax Provision | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -4.06M | 10.83M | 10.88M | 19.24M | 13.01M |
| Net Income | 1.46M | 10.04M | 17.23M | 26.32M | 36.09M | 55.65M | 22.38M | 26.30M | 33.47M | 28.41M | 30.60M | 47.96M | 41.38M | 44.15M | - | 62.46M | 53.32M | 62.06M | 61.56M | 19.11M |
| Diluted EPS | 0.00 | 0.02 | 0.05 | 0.09 | 0.17 | 0.26 | 0.10 | 0.12 | 0.16 | 0.13 | 0.15 | 0.24 | 0.21 | 0.22 | - | 0.31 | 0.27 | 0.31 | 0.31 | 0.10 |
| R&D Expense | 10.04M | 9.87M | 11.41M | 13.24M | 15.46M | 16.23M | 19.02M | 19.10M | 20.52M | 21.93M | 19.96M | 19.95M | 22.57M | 23.24M | 22.42M | - | 26.80M | 30.20M | 34.59M | - |
Profit & Loss (Annual)
Figures in USD.
| Metric | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|
| Revenue | 116.39M | 206.90M | 343.55M | 419.05M | 475.42M | 570.40M | 644.86M |
| Gross Profit | 101.49M | 175.70M | 303.76M | 365.56M | 424.75M | 514.52M | 574.54M |
| Operating Income | 22.16M | 53.30M | 113.54M | 125.11M | 163.88M | 227.80M | 214.92M |
| Net Income | 29.74M | 50.21M | 154.78M | 112.82M | 147.58M | 223.19M | 196.05M |
| Diluted EPS | 0.13 | 0.23 | 0.70 | 0.53 | 0.72 | 1.11 | 0.98 |
| R&D Expense | 32.44M | 43.87M | 62.35M | 80.19M | 81.98M | 93.04M | 130.70M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|
| Total Assets | - | - | 251.72M | 991.36M | 1.14B | 1.08B | 1.26B | 1.12B |
| Total Equity | -32.94M | 1.14M | 66.74M | 878.59M | 966.12M | 901.40M | 1.08B | 950.84M |
| Cash & Equivalents | - | - | 66.39M | 112.81M | 158.03M | 96.78M | 209.61M | 219.18M |
| Total Liabilities | - | - | 103.52M | 112.76M | 170.77M | 177.98M | 181.68M | 172.85M |
| Current Liabilities | - | - | 102.04M | 111.28M | 139.51M | 147.25M | 156.26M | 154.97M |
Cash Flows (Annual)
Figures in USD.
| Metric | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|
| Operating Cash Flow | 26.20M | 82.97M | 126.58M | 179.60M | 184.10M | 273.26M | 326.46M |
| Investing Cash Flow | -13.10M | -70.42M | -640.57M | -59.92M | 31.19M | -29.30M | 147.17M |
| Financing Cash Flow | 1.72M | 5.41M | 560.41M | -74.46M | -276.52M | -131.14M | -464.06M |
| Capital Expenditure | -285.00K | -245.00K | -1.91M | -1.70M | -147.00K | -0 | -0 |
| Free Cash Flow | 25.91M | 82.73M | 124.66M | 177.90M | 183.95M | 273.26M | 326.46M |
| Share Buybacks | 0 | 2.02M | 2.70M | 85.32M | 280.72M | 120.29M | 431.65M |
Ratios (Annual)
Figures in %.
| Metric | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|
| Gross Margin % | 87.2% | 84.9% | 88.4% | 87.2% | 89.3% | 90.2% | 89.1% |
| Operating Margin % | 19.0% | 25.8% | 33.0% | 29.9% | 34.5% | 39.9% | 33.3% |
| Net Margin % | 25.5% | 24.3% | 45.1% | 26.9% | 31.0% | 39.1% | 30.4% |
| ROE % | 2,617.7% | 75.2% | 17.6% | 11.7% | 16.4% | 20.6% | 20.6% |
| ROCE % | - | 35.6% | 12.9% | 12.5% | 17.6% | 20.6% | 22.2% |
Shareholding Pattern
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for DOCS
Ahead of Doximity (DOCS) Q1 Earnings: Get Ready With Wall Street Estimates for Key Metrics
Looking beyond Wall Street's top-and-bottom-line estimate forecasts for Doximity (DOCS), delve into some of its key metrics to gain a deeper insight into the company's potential performance for the quarter ended June 2026.…
Doximity (DOCS) Stock May Be 41% Undervalued As Cash Flow Holds Up
Doximity stock has had a difficult run over the past year, yet current valuation work suggests the market price may sit well below an intrinsic value estimate based on a Discounted Cash Flow model. With traditional market multiples also poi…
2 Profitable Stocks to Keep an Eye On and 1 We Turn Down
Not all profitable companies are built to last - some rely on outdated models or unsustainable advantages. Just because a business is in the green today doesn’t mean it will thrive tomorrow.
1 Stock Under $50 to Consider Right Now and 2 We Ignore
The $10-50 price range often includes mid-sized businesses with proven track records and plenty of growth runway ahead. They also usually carry less risk than penny stocks, though they’re not immune to volatility as many lack the scale adva…
Doximity (DOCS) Laps the Stock Market: Here's Why
Doximity (DOCS) concluded the recent trading session at $20.99, signifying a +2.79% move from its prior day's close.
2 Reasons to Like DOCS (and 1 Not So Much)
What a brutal six months it’s been for Doximity. The stock has dropped 48.2% and now trades at $21.15, rattling many shareholders. This was partly driven by its softer quarterly results and might have investors contemplating their next move…
DOCS — Frequently Asked Questions
What is the current share price of DOCS?
As of 2026-08-05 17:25 PDT, DOCS trades at $21.63 on NASDAQ/NYSE. Its 52-week range is $18.01 to $75.12.
What is the P/E ratio of DOCS?
DOCS trades at a trailing price-to-earnings (P/E) ratio of 22.07.
What is the return on equity (ROE) of DOCS?
DOCS has a return on equity (ROE) of 20.62%. Its return on capital employed (ROCE) is 22.19%.
Is DOCS a good stock to buy?
This page provides a data-driven analysis of DOCS, including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.